Tallahassee Neurological Clinic

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• Alzheimer disease2 trials
• Brain aneurysm2 trials
• Epilepsy1 trial
• High blood pressure1 trial
• Spinal cord injury1 trial
• Stroke1 trial

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 41 trial

Status

• Completed5 trials
• Active, not recruiting4 trials
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Novartis Pharmaceuticals3 trials
• Eli Lilly and Company2 trials
• Imperative Care, Inc.1 trial
• Mayo Clinic1 trial
• Robert F. James1 trial
• and 3 more

Running trials

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Sharon Devore

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

  NCT04195568· Stryker Neurovascular· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis1 recruiting

Closed trials

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

  NCT04129125· Imperative Care, Inc.· Source

• Completed

  Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

  NCT04683848· Phase 2· Tanabe Pharma America, Inc.· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Mayo Clinic· Source